Better life with immune tolerance

Reinventing MS therapy

RED4MS is a unique approach to treat and prevent multiple sclerosis (“MS”). It has been developed over the past decade and has successfully passed phase Ib clinical testing. Cellerys will start a multi-center phase IIa trial in 2022 as the next important milestone to bring RED4MS to patients.